‘Compassion Vs Competitiveness’ Dilemma at Novo Nordisk
<< Previous
Introduction
“How to strike the right balance between business and global health? Again, we were challenged by stakeholders…,” quipped Lise Kingo (Kingo), Executive vice president and chief of staffs, Novo Nordisk. The Danish pharmaceutical company, Novo Nordisk, had gained global recognition as a champion of sustainability for a number of sustainability related initiatives that it had taken over the years.
Over the years, Novo Nordisk’s business grew substantially and it emerged as a leader in the global insulin market. In the new millennium, Novo Nordisk’s new sustainability strategy placed global health at the center of its sustainability initiatives. According to Novo Nordisk’s vision statement, the company strove to find the right balance between compassion and competitiveness.
|
|
or |
|
or |
PayPal (11 USD)
|
|
From then on, Novo Nordisk started selling its products at a subsidized price in some of the poorest countries around the world. Despite all the efforts that it took to protect the interests of all its stakeholders, in 2010, Novo Nordisk was severely criticized by patients and NGOs when it stopped selling its drugs in Greece when the crisis ridden government there ordered a 25 percent cut in the prices of all medicines sold in the country.
About Novo Nordisk - Next Page>>